Blog
There is no evidence of additional benefit of faricimab compared to comparator therapies for the treatment of macular edema
29
Dec
Dec
As of July 2024, faricimab is also approved in Europe for the treatment of visual disturbances caused by macular edema secondary to retinal vein occlusion. The German Institute for Healthcare Quality and Efficiency (IQWiG) has now investigated whether faricimab provides benefits to patients compared to ranibizumab or aflibercept as part of an early benefit assessment. […]